Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EMN 2018 | Managing plasma cell leukemia: Pls, IMiDs, alkylating agents and antibodies

Torben Plesner • 4 May 2018
EMN 2018
Multiple Myeloma Antibodies Carfilzomib Daratumumab Lenalidomide Pomalidomide

The incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma (MM). In this video, Torben Plesner, MD, from the University of Southern Denmark, Vejle, Denmark, discusses the variety of agents used in the therapeutic management of MM. This interview was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.

More from Torben Plesner

Mechanistic insights into the resistance to anti-CD38 therapy 4:43
Mechanistic insights into the resistance to anti-CD38 therapy
Torben Plesner • 14 Sep 2019
Daratumumab practical considerations in MM 3:36
Daratumumab practical considerations in MM
Torben Plesner • 16 May 2019
Novel drug delivery method to prevent daratumumab infusion-related reactions in MM 2:08
Novel drug delivery method to prevent daratumumab infusion-related reactions in MM
Torben Plesner • 19 Jul 2018
The challenges of treating plasma cell leukemia 3:10
The challenges of treating plasma cell leukemia
Torben Plesner • 4 May 2018

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals